(103) found that c-Met inhibitors combined with PD-1/PD-L1 inhibitors could achieve better efficacy against PC in situ and subcutaneous mouse models, indicating that combination of c-Met and PD-1/PD-L1 inhibitors may be a charming choice for PC treatment. This evidence concerns the gene MET and pachyonychia congenita.